Cargando…
Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis
BACKGROUND: Pirfenidone was recently approved for treatment of idiopathic pulmonary fibrosis. However, the therapeutic dose of pirfenidone is very high, causing side effects that limit its doses and therapeutic effectiveness. Understanding the molecular mechanisms of action of pirfenidone could impr...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994235/ https://www.ncbi.nlm.nih.gov/pubmed/27549302 http://dx.doi.org/10.1186/s12931-016-0418-4 |
_version_ | 1782449286247612416 |
---|---|
author | Xie, Yan Jiang, Haihong Zhang, Qian Mehrotra, Suneet Abel, Peter W. Toews, Myron L. Wolff, Dennis W. Rennard, Stephen Panettieri, Reynold A. Casale, Thomas B. Tu, Yaping |
author_facet | Xie, Yan Jiang, Haihong Zhang, Qian Mehrotra, Suneet Abel, Peter W. Toews, Myron L. Wolff, Dennis W. Rennard, Stephen Panettieri, Reynold A. Casale, Thomas B. Tu, Yaping |
author_sort | Xie, Yan |
collection | PubMed |
description | BACKGROUND: Pirfenidone was recently approved for treatment of idiopathic pulmonary fibrosis. However, the therapeutic dose of pirfenidone is very high, causing side effects that limit its doses and therapeutic effectiveness. Understanding the molecular mechanisms of action of pirfenidone could improve its safety and efficacy. Because activated fibroblasts are critical effector cells associated with the progression of fibrosis, this study investigated the genes that change expression rapidly in response to pirfenidone treatment of pulmonary fibroblasts and explored their contributions to the anti-fibrotic effects of pirfenidone. METHODS: We used the GeneChip microarray to screen for genes that were rapidly up-regulated upon exposure of human lung fibroblast cells to pirfenidone, with confirmation for specific genes by real-time PCR and western blots. Biochemical and functional analyses were used to establish their anti-fibrotic effects in cellular and animal models of pulmonary fibrosis. RESULTS: We identified Regulator of G-protein Signaling 2 (RGS2) as an early pirfenidone-induced gene. Treatment with pirfenidone significantly increased RGS2 mRNA and protein expression in both a human fetal lung fibroblast cell line and primary pulmonary fibroblasts isolated from patients without or with idiopathic pulmonary fibrosis. Pirfenidone treatment or direct overexpression of recombinant RGS2 in human lung fibroblasts inhibited the profibrotic effects of thrombin, whereas loss of RGS2 exacerbated bleomycin-induced pulmonary fibrosis and mortality in mice. Pirfenidone treatment reduced bleomycin-induced pulmonary fibrosis in wild-type but not RGS2 knockout mice. CONCLUSIONS: Endogenous RGS2 exhibits anti-fibrotic functions. Upregulated RGS2 contributes significantly to the anti-fibrotic effects of pirfenidone. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12931-016-0418-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4994235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49942352016-08-24 Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis Xie, Yan Jiang, Haihong Zhang, Qian Mehrotra, Suneet Abel, Peter W. Toews, Myron L. Wolff, Dennis W. Rennard, Stephen Panettieri, Reynold A. Casale, Thomas B. Tu, Yaping Respir Res Research BACKGROUND: Pirfenidone was recently approved for treatment of idiopathic pulmonary fibrosis. However, the therapeutic dose of pirfenidone is very high, causing side effects that limit its doses and therapeutic effectiveness. Understanding the molecular mechanisms of action of pirfenidone could improve its safety and efficacy. Because activated fibroblasts are critical effector cells associated with the progression of fibrosis, this study investigated the genes that change expression rapidly in response to pirfenidone treatment of pulmonary fibroblasts and explored their contributions to the anti-fibrotic effects of pirfenidone. METHODS: We used the GeneChip microarray to screen for genes that were rapidly up-regulated upon exposure of human lung fibroblast cells to pirfenidone, with confirmation for specific genes by real-time PCR and western blots. Biochemical and functional analyses were used to establish their anti-fibrotic effects in cellular and animal models of pulmonary fibrosis. RESULTS: We identified Regulator of G-protein Signaling 2 (RGS2) as an early pirfenidone-induced gene. Treatment with pirfenidone significantly increased RGS2 mRNA and protein expression in both a human fetal lung fibroblast cell line and primary pulmonary fibroblasts isolated from patients without or with idiopathic pulmonary fibrosis. Pirfenidone treatment or direct overexpression of recombinant RGS2 in human lung fibroblasts inhibited the profibrotic effects of thrombin, whereas loss of RGS2 exacerbated bleomycin-induced pulmonary fibrosis and mortality in mice. Pirfenidone treatment reduced bleomycin-induced pulmonary fibrosis in wild-type but not RGS2 knockout mice. CONCLUSIONS: Endogenous RGS2 exhibits anti-fibrotic functions. Upregulated RGS2 contributes significantly to the anti-fibrotic effects of pirfenidone. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12931-016-0418-4) contains supplementary material, which is available to authorized users. BioMed Central 2016-08-22 2016 /pmc/articles/PMC4994235/ /pubmed/27549302 http://dx.doi.org/10.1186/s12931-016-0418-4 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Xie, Yan Jiang, Haihong Zhang, Qian Mehrotra, Suneet Abel, Peter W. Toews, Myron L. Wolff, Dennis W. Rennard, Stephen Panettieri, Reynold A. Casale, Thomas B. Tu, Yaping Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis |
title | Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis |
title_full | Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis |
title_fullStr | Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis |
title_full_unstemmed | Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis |
title_short | Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis |
title_sort | upregulation of rgs2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994235/ https://www.ncbi.nlm.nih.gov/pubmed/27549302 http://dx.doi.org/10.1186/s12931-016-0418-4 |
work_keys_str_mv | AT xieyan upregulationofrgs2anewmechanismforpirfenidoneameliorationofpulmonaryfibrosis AT jianghaihong upregulationofrgs2anewmechanismforpirfenidoneameliorationofpulmonaryfibrosis AT zhangqian upregulationofrgs2anewmechanismforpirfenidoneameliorationofpulmonaryfibrosis AT mehrotrasuneet upregulationofrgs2anewmechanismforpirfenidoneameliorationofpulmonaryfibrosis AT abelpeterw upregulationofrgs2anewmechanismforpirfenidoneameliorationofpulmonaryfibrosis AT toewsmyronl upregulationofrgs2anewmechanismforpirfenidoneameliorationofpulmonaryfibrosis AT wolffdennisw upregulationofrgs2anewmechanismforpirfenidoneameliorationofpulmonaryfibrosis AT rennardstephen upregulationofrgs2anewmechanismforpirfenidoneameliorationofpulmonaryfibrosis AT panettierireynolda upregulationofrgs2anewmechanismforpirfenidoneameliorationofpulmonaryfibrosis AT casalethomasb upregulationofrgs2anewmechanismforpirfenidoneameliorationofpulmonaryfibrosis AT tuyaping upregulationofrgs2anewmechanismforpirfenidoneameliorationofpulmonaryfibrosis |